Inventiva (IVA) Total Non-Current Liabilities (2018 - 2025)
Inventiva (IVA) recorded quarterly Total Non-Current Liabilities of $233.6 million in Q4 2025, down 99.84% quarter-over-quarter from $146.5 billion in Q2 2025, and up 108.4% on a YoY basis from $112.1 million in Q4 2024.
Inventiva (IVA) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Inventiva's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $233.6 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 108.4% year-over-year to $233.6 million; the TTM figure through Dec 2025 stood at $233.6 million (up 108.4% YoY), while the FY2025 annual figure was $233.6 million, up 108.4% from the prior year.
- Total Non-Current Liabilities was $233.6 million for Q4 2025 at Inventiva, down from $146.5 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $146.5 billion in Q2 2025 to a low of $11.7 million in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $18.1 billion across 5 years, with a median of $55.3 million in 2023.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities dropped 28.62% in 2021, then surged 93614.43% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $11.7 million in 2021, then jumped by 245.99% to $40.6 million in 2022, then surged by 36.19% to $55.3 million in 2023, then jumped by 102.53% to $112.1 million in 2024, then surged by 108.4% to $233.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $233.6 million (Q4 2025), $146.5 billion (Q2 2025), and $112.1 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 42,980.09 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 64.76 Mn |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | 233.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 233.57 Mn |
| Jun 30, 2025 | 146.48 Bn |
| Dec 31, 2024 | 112.08 Mn |
| Dec 31, 2023 | 55.34 Mn |
| Dec 31, 2022 | 40.63 Mn |
| Jun 30, 2022 | 15.60 Bn |
| Dec 31, 2021 | 11.74 Mn |
| Jun 30, 2021 | 16.65 Mn |
| Mar 31, 2021 | 16.76 Mn |
| Dec 31, 2020 | 16.45 Mn |
| Jun 30, 2020 | 1.97 Mn |
| Dec 31, 2019 | 1.89 Mn |
| Dec 31, 2018 | 3.58 Mn |